Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Twist Bioscience Corp (TWST) vs UnitedHealth Group Inc (UNH) Price & Performance

Twist Bioscience CorpTrade
UnitedHealth Group IncTrade

Price performance (Past 24H)

Key statistics

Twist Bioscience Corp vs UnitedHealth Group Inc — how do they compare? Twist Bioscience Corp trades at $124.64 (market cap $7.72B), while UnitedHealth Group Inc trades at $405.33 (market cap $361.00B). The key difference: UnitedHealth Group Inc is far larger — about 46.8× Twist Bioscience Corp's market cap, and UnitedHealth Group Inc pays a 2.31% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

TWSTUNH
Market Cap
$7.72B$361.00B
Sector
HealthHealth
52-Week High
$124.88$436.35
52-Week Low
$24.16$259.02
Enterprise Value
$7.65B$402.86B
Dividend Yield
2.31%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.

Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.

UnitedHealth Group Inc

UnitedHealth Group (UNH) trades at $408.74, showing modest daily gains of 0.41% amid a bearish technical signal. The company demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust analyst support (82.7% buy ratings). Recent developments include dividend payments and strategic initiatives to streamline pediatric care authorizations, positioning UNH well in the healthcare sector.

UNH presents a compelling investment case with strong cash flow generation and market leadership, though investors face risks from regulatory scrutiny and margin compression. The stock trades at a discount to analyst consensus target of $476.50, offering potential upside if operational improvements and growth initiatives materialize as projected.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST

About UnitedHealth Group Inc

UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.

Read more on UNH